• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前瞻性新辅助治疗及手术后,病理T0(ypT0)食管鳞状细胞癌中残留淋巴结转移的肿瘤学结局

Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.

作者信息

Cho Hyun Jin, Kim Yong-Hee, Kim Hyeong Ryul, Kim Dong Kwan, Park Seung-Il, Kim Jong Hoon, Kim Sung-Bae

机构信息

Department of Thoracic and Cardiovascular Surgery, Gachon University Gil Medical Center, Incheon, Korea.

出版信息

Ann Surg Oncol. 2015;22(6):1851-7. doi: 10.1245/s10434-014-4195-3. Epub 2014 Oct 25.

DOI:10.1245/s10434-014-4195-3
PMID:25344308
Abstract

BACKGROUND

Some esophageal cancer patients may have residual nodal metastases following pathologic complete response (pCR) of the primary tumor after neoadjuvant chemoradiotherapy (CRT). This study examines the prognosis according to lymph node metastases in pathologic T0 patients who received neoadjuvant CRT followed by surgery for esophageal squamous cell carcinoma (SCC).

METHODS

Prospectively-collected data from patients who underwent protocol-based esophageal resection and reconstruction after neoadjuvant CRT for esophageal SCC from 2000 to 2010 at the Asan Medical Center, Seoul, Korea, were retrospectively studied. Overall survival (OS), recurrence-free survival (RFS), and risk factors for ypT0N1 were analyzed and compared with ypT0N0.

RESULTS

A total of 211 patients underwent prospective, protocol-based esophageal resection and reconstruction after neoadjuvant CRT for esophageal SCC. Of these, 123 patients had a pCR of the primary tumor and were enrolled in this study. Lymph node status was ypT0N0 in 103 patients and ypT0N1 in 20 patients. The two groups did not show significant differences in sex, initial clinical stage, tumor location, and histologic grade. Recurrence occurred in 13 patients (12.6 %) with ypT0N0 and six patients (30.0 %) with ypT0N1, respectively (p = 0.083). Five-year OS and RFS of ypT0N1 were 42.8 ± 13.9 and 41.7 ± 12.8 %, respectively. Survival was compared between the two groups using a log-rank test, and there were no significant differences for OS or RFS.

CONCLUSIONS

Residual lymph node metastases did not significantly influence prognosis in pathologic T0 patients who received neoadjuvant CRT followed by surgery for esophageal SCC.

摘要

背景

部分食管癌患者在新辅助放化疗(CRT)后原发肿瘤达到病理完全缓解(pCR),但仍可能存在残留淋巴结转移。本研究旨在探讨接受新辅助CRT后行手术治疗的食管鳞状细胞癌(SCC)患者中,病理T0患者淋巴结转移情况与预后的关系。

方法

回顾性研究2000年至2010年在韩国首尔峨山医学中心接受新辅助CRT后行基于方案的食管切除重建术的食管SCC患者的前瞻性收集数据。分析总生存(OS)、无复发生存(RFS)以及ypT0N1的危险因素,并与ypT0N0进行比较。

结果

共有211例患者在新辅助CRT后接受了基于方案的食管切除重建术治疗食管SCC。其中,123例患者原发肿瘤达到pCR并纳入本研究。103例患者淋巴结状态为ypT0N0,20例患者为ypT0N1。两组在性别、初始临床分期、肿瘤位置和组织学分级方面无显著差异。ypT0N0组和ypT0N1组分别有13例(12.6%)和6例(30.0%)出现复发(p = 0.083)。ypT0N1组的5年OS和RFS分别为42.8±13.9%和41.7±12.8%。采用对数秩检验比较两组生存情况,OS或RFS均无显著差异。

结论

对于接受新辅助CRT后行手术治疗的食管SCC病理T0患者,残留淋巴结转移对预后无显著影响。

相似文献

1
Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.前瞻性新辅助治疗及手术后,病理T0(ypT0)食管鳞状细胞癌中残留淋巴结转移的肿瘤学结局
Ann Surg Oncol. 2015;22(6):1851-7. doi: 10.1245/s10434-014-4195-3. Epub 2014 Oct 25.
2
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.新辅助放化疗后原发肿瘤完全缓解的食管癌患者残留淋巴结疾病的预后价值。
J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.
3
Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis.新辅助放化疗后行食管切除术治疗初治可切除的伴有多发淋巴结转移的食管鳞状细胞癌。
Dis Esophagus. 2005;18(6):388-97. doi: 10.1111/j.1442-2050.2005.00521.x.
4
The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases.新辅助放化疗对伴有多发淋巴结转移的局部晚期食管癌的有效性。
Ann Surg Oncol. 2014 Sep;21(9):2845-9. doi: 10.1245/s10434-014-3688-4. Epub 2014 Apr 14.
5
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.新辅助放化疗后食管癌的淋巴结清扫。
Ann Surg Oncol. 2013 Sep;20(9):3038-43. doi: 10.1245/s10434-013-2988-4. Epub 2013 Apr 28.
6
Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy.对于能够耐受经胸段食管癌切除术的食管鳞状细胞癌患者,比较经胸段食管癌切除术与根治性放化疗作为初始治疗方法的效果。
Ann Surg Oncol. 2015;22(6):1866-73. doi: 10.1245/s10434-014-4337-7. Epub 2015 Jan 7.
7
Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer.临床 T1bN0M0 期食管癌患者根治性食管切除术与根治性放化疗的比较。
Ann Surg Oncol. 2012 Jul;19(7):2135-41. doi: 10.1245/s10434-012-2231-8.
8
Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?新辅助放化疗与手术治疗食管鳞癌的时间间隔:手术延迟是否影响预后?
Ann Surg Oncol. 2013 Dec;20(13):4245-51. doi: 10.1245/s10434-013-3139-7.
9
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.局部晚期食管癌的淋巴结转移:新辅助治疗如何改变其频率和分布。
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.
10
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.与单纯手术相比,新辅助放化疗后的食管癌患者具有不同的复发模式。
Ann Surg Oncol. 2013 Nov;20(12):4008-15. doi: 10.1245/s10434-013-3102-7. Epub 2013 Jul 10.

引用本文的文献

1
Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.食管鳞状细胞癌新辅助放化疗或放疗后不同病理退缩类型的生存和复发模式的多机构分析
Cancer Med. 2025 Feb;14(4):e70676. doi: 10.1002/cam4.70676.
2
Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.新辅助放化疗及手术后病理状态在食管鳞状细胞癌中的预后作用
BMC Cancer. 2025 Jan 10;25(1):61. doi: 10.1186/s12885-025-13465-w.
3
Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
新辅助放化疗后病理 T0 食管鳞癌患者的肿瘤学结局。
Cancer Control. 2024 Jan-Dec;31:10732748241284905. doi: 10.1177/10732748241284905.
4
ypT0N+: the unusual patient with pathological complete tumor response but with residual lymph node disease after neoadjuvant chemoradiation for esophageal cancer, what's up?ypT0N+:食管癌新辅助放化疗后出现肿瘤病理完全缓解但伴有残留淋巴结疾病的特殊患者,怎么回事?
J Thorac Dis. 2018 May;10(5):2771-2778. doi: 10.21037/jtd.2018.04.136.
5
Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.转移性淋巴结肿瘤的病理性肿瘤消退分级可预测食管癌患者的预后。
Cancer Sci. 2018 Jun;109(6):2046-2055. doi: 10.1111/cas.13596. Epub 2018 May 3.
6
Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy.诊断时初始全内镜肿瘤长度在接受食管切除术的可手术性食管鳞状细胞癌中的预后作用,无论是否接受新辅助同步放化疗。
J Thorac Dis. 2017 Sep;9(9):3193-3207. doi: 10.21037/jtd.2017.08.108.
7
Remnant lymph node metastases after neoadjuvant therapy and surgery in patients with pathologic T0 esophageal carcinoma impact on prognosis: A systematic review and meta-analysis.新辅助治疗和手术后病理T0期食管癌患者的残留淋巴结转移对预后的影响:一项系统评价和荟萃分析
Medicine (Baltimore). 2017 Jun;96(26):e7342. doi: 10.1097/MD.0000000000007342.
8
Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy.残留淋巴结状态是术前放疗后病理T0期食管鳞状细胞癌的独立预后因素。
Radiat Oncol. 2015 Jul 11;10:142. doi: 10.1186/s13014-015-0450-4.